Abcellera Biologics Inc
NASDAQ:ABCL
Abcellera Biologics Inc
NASDAQ:ABCL
Price:
3.02
USD
-0.66%
Market Closed
Market Cap:
$904m
Relative Value
The Relative Value of one
ABCL
stock under the Base Case scenario is
1.31
USD.
Compared to the current market price of 3.02 USD,
Abcellera Biologics Inc
is
Overvalued by 57%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ABCL
Relative Value
Base Case
1.31
USD
Overvaluation 57%
Multiples Across Competitors
ABCL Competitors Multiples
Abcellera Biologics Inc Competitors
Abcellera Biologics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
903m USD | 26.2 | -5.4 | -1.8 | -1.6 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD | 383.3 | 4 538.3 | 1 438.8 | 3 074.2 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
193.7B USD | 4.4 | 29 | 20.2 | 27.1 | |
| US |
|
Danaher Corp
NYSE:DHR
|
149B USD | 6.1 | 41.2 | 22.8 | 34.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
136.2T KRW | 8.4 | 29 | 29.1 | 38.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
36B CHF | 5.6 | 38.4 | 28.2 | 28.2 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
291.5B CNY | 6.6 | 19.4 | 19.7 | 19.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.8B USD | 5 | 26.8 | 19.6 | 23.2 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.4B USD | 7.1 | 32.7 | 24.1 | 26.8 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.5B USD | 1.7 | 20.1 | 11.4 | 17 | |
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
169.3B HKD | 7.5 | 35.7 | 25.2 | 25.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
